Exact Sciences Corporation (NASDAQ:EXAS) insider Graham Peter Lidgard sold 81,025 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $3,821,139.00. Following the transaction, the insider now directly owns 366,519 shares in the company, valued at $17,285,036.04. The sale was disclosed in a filing with the SEC, which is available through this link.

Graham Peter Lidgard also recently made the following trade(s):

  • On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock. The shares were sold at an average price of $40.81, for a total value of $3,088,623.23.
  • On Friday, September 1st, Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock. The shares were sold at an average price of $41.49, for a total value of $1,899,204.75.

Shares of Exact Sciences Corporation (NASDAQ EXAS) opened at 47.99 on Thursday. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $50.65. The company’s 50-day moving average price is $42.81 and its 200 day moving average price is $34.86. The firm’s market capitalization is $5.72 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. On average, equities research analysts forecast that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Graham Peter Lidgard Sells 81,025 Shares of Exact Sciences Corporation (EXAS) Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/graham-peter-lidgard-sells-81025-shares-of-exact-sciences-corporation-exas-stock/1609095.html.

Several research analysts recently issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 target price (up from $45.00) on shares of Exact Sciences Corporation in a research report on Tuesday. Zacks Investment Research raised Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a research report on Tuesday, September 26th. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 target price (up from $45.00) on shares of Exact Sciences Corporation in a research report on Thursday, September 21st. BidaskClub raised Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Finally, BTIG Research reaffirmed a “buy” rating and set a $45.00 target price (up from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $43.11.

A number of hedge funds have recently modified their holdings of the stock. Advisor Group Inc. increased its position in Exact Sciences Corporation by 0.8% in the 2nd quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 65 shares during the period. Stifel Financial Corp increased its position in Exact Sciences Corporation by 1.5% in the 1st quarter. Stifel Financial Corp now owns 21,475 shares of the medical research company’s stock valued at $506,000 after acquiring an additional 310 shares during the period. Prudential Financial Inc. increased its position in Exact Sciences Corporation by 3.0% in the 1st quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock valued at $263,000 after acquiring an additional 320 shares during the period. Ameritas Investment Partners Inc. increased its position in Exact Sciences Corporation by 5.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock valued at $341,000 after acquiring an additional 511 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its position in Exact Sciences Corporation by 17.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares during the period. Hedge funds and other institutional investors own 85.23% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.